Compositions for a dietary supplement to manage senescent cells
US-2024390346-A1 · Nov 28, 2024 · US
Compositions and methods for the treatment of Plasmodium falciparum malaria
US12544357B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12544357-B2 |
| Application number | US-202218279031-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2022 |
| Priority date | Feb 26, 2021 |
| Publication date | Feb 10, 2026 |
| Grant date | Feb 10, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express PfGARP.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating P. falciparum malaria comprising administering to a subject in need thereof a therapeutically-effective amount of a small molecule therapeutic agent that specifically binds to P. falciparum glutamic-acid-rich proteins (PfGARP) located on the exofacial surface of red blood cells (RBCs) infected with P. falciparum , wherein the small molecule therapeutic agent is: 2 . The method of claim 1 , wherein the small molecule therapeutic agent is in a pharmaceutical formulation. 3 . The method of claim 1 , wherein the method does not activate an apoptosis in subject host cells or parasite cells that do not express the PfGARP.
Assignees
Inventors
Classifications
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
containing a six-membered ring with oxygen as a ring hetero atom · CPC title
not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12544357B2 cover?
- Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express PfGARP.
- Who is the assignee on this patent?
- Univ Brown, Florida Atlantic Univ Board Of Trustees
- What technology area does this patent fall under?
- Primary CPC classification A61K31/357. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).